All News

Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.

Ofatumumab (Kesimpta; Novartis) demonstrated a sustained efficacy as a first-line, continuous treatment for patients recently diagnosed and treatment-naïve with relapsing multiple sclerosis.

PAPs in this model can significantly reduce OOP costs regardless of the pharmacy setting.

Conversations and counseling points should be tailored to patients’ individual needs and treatment goals

Laura Gillespie, PharmD, discusses the impact of pharmacist-led initiatives on health care–associated C diff rates for health care systems.

Investigators found that younger age groups had significantly longer lengths of stay compared to those older than 75 years.

The trial will compared the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and pembrolizumab for metastatic non-squamous non-small cell lung cancer.

Optical glucose sensing techniques have been reported, but they require complex optical instrumentations found in laboratories, so feasibility for patient use has been challenging.

Ocrelizumab (Ocrevus; Roche) is being investigated as a twice yearly 10-minute subcutaneous injection compared to the intravenous infusion formulation.

Sharing data and a personal recommendation can make a difference in a patient’s life

Proper diagnosis and selection of products is crucial to management of hay fever

The significant surge in oncology drug shortages in 2023 particularly affected essential chemotherapeutic drugs.

Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.

Retinoic acid, an active form of vitamin A, is crucial for the stem cells to depart lineage plasticity which get separated into hair cells or epidermal cells in vitro.

The primary endpoint of the study was clinical remission at week 52 with vedolizumab

Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.

With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.

In a trial that compared gepotidacin to ceftriaxone plus azithromycin in patients with urogenital gonorrhea, gepotidacin presented a 92.6% microbiological success rate.

Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.

Regardless of how this fits into workflow, pharmacists can play a significant role in counseling patients on nutrition and holistic health.

Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases

Speaker Monica Diaz describes the detrimental impact climate change has on the transmission and increases in infectious disease cases.

The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.

Tara Schneider, PharmD, and her husband, Chuck Schneider, MBA, offer expanded clinical services in their Louisville, Kentucky, pharmacy.

The results displayed well tolerability and safety with Abrysvo, meeting the study’s co-primary endpoint of immunogenicity and primary safety

Adrijana Kekic, PharmD, a pharmacogenomics clinical specialist with Mayo Clinic in Phoenix, Arizona, discussed current guidelines for pharmacogenomics.

With the first FDA-approved option hitting shelves soon, pharmacists can advise patients on the best methods to prevent pregnancy